Express Mail No.: EV335856896US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Dingivan et al.

Application No.: Not Yet Assigned Art Unit: Not Yet Assigned

Filing Date: On an Even Date Herewith Examiner: Not Yet Assigned

For: METHODS OF PREVENTING OR Attorney Docket No.: 10271-116-999

TREATING T CELL MALIGNANCIES BY ADMINISTERING CD2 ANTAGONISTS

TRANSMITTAL OF SEQUENCE LISTING

Commissioner For Patents PO Box 1450 Alexandria, Virginia 22313-1450

SIR:

In connection with the above-identified application, and in accordance with 37 C.F.R. § 1.821, Applicants submit herewith a Sequence Listing in paper and computer-readable format pursuant to 37 C.F.R. § 1.821(c) and (e).

I hereby state that the content of the paper and computer-readable copies of the Sequence Listing, submitted in accordance with 37 C.F.R. § 1.821(c) and (e), respectively, are the same.

Respectfully submitted,

Date September 5, 2003

 $10 \times 10^{\circ}$ $10 \times 10^{\circ}$ $10 \times 10^{\circ}$ $10 \times 10^{\circ}$ $10 \times 10^{\circ}$

Margaret B. Brivanlou (Reg. No.)

PENNIE & EDMONDS LLP 1155 Avenue of the Americas New York, New York 10036-2711 (212) 790-9090

Enclosures